Form 4: SeaStar Medical CMO Kevin Chung Awarded 15,000 RSUs

SeaStar Medical Holding Corp's Chief Medical Officer, Kevin Chung, was granted 15,000 Restricted Stock Units, aligning management interests with shareholders.

Summary

• Kevin Chung, Chief Medical Officer of SeaStar Medical Holding Corp (ICU), was granted 15,000 shares of Common Stock as a Restricted Stock Unit (RSU) award.
• The transaction date for this award was February 6, 2026.
• The RSU award vests in equal installments on the first, second, and third anniversaries of February 6, 2026.
• Following this transaction, Kevin Chung beneficially owns 20,819 shares of Common Stock.
• The RSU award was granted at a price of $0 per share, typical for such grants.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the RSU award aligns the Chief Medical Officer's long-term interests with those of shareholders and serves as a retention incentive.

Positives

• The grant of 15,000 Restricted Stock Units to the Chief Medical Officer demonstrates a commitment to retaining key executive talent.
• This RSU award aligns the Chief Medical Officer's long-term financial interests directly with the performance of SeaStar Medical Holding Corp and its shareholders.
• Increased insider ownership can signal confidence in the company's future prospects.

Future Outlook

The RSU award's vesting schedule over three years indicates a long-term incentive structure for the Chief Medical Officer, suggesting an expectation of continued service and contribution to the company's future performance.

Industry Context

StockSavvy.ai notes that RSU awards are a common form of equity compensation in the biotechnology and medical device industries, used to attract, retain, and incentivize key executives by aligning their compensation with long-term shareholder value creation. This practice is standard across publicly traded companies, including peers in the medical technology sector.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for executive compensation is a widely adopted practice across the U.S. public markets, including companies comparable to SeaStar Medical Holding Corp in the medical technology and biotechnology sectors.
• The vesting schedule over three years is typical for RSU grants, designed to encourage long-term commitment and performance, similar to practices seen at companies like Medtronic (MDT) or Boston Scientific (BSX) for their executive compensation plans.
• The grant of 15,000 shares to a Chief Medical Officer is within the expected range for an executive at a company of SeaStar Medical's size and stage, reflecting standard compensation benchmarks for retaining specialized talent in the medical field.

Stakeholder Impact

• Shareholders: The RSU grant aligns the Chief Medical Officer's interests with shareholders, potentially leading to more focused efforts on long-term value creation.
• Employees: This type of executive compensation can signal stability and a commitment to retaining key leadership, which can positively influence employee morale.

Next Steps

• The RSU award will vest in equal installments on the first, second, and third anniversaries of February 6, 2026.

Key Dates

Keywords

SeaStar Medical Holding Corp, ICU, Kevin Chung, Chief Medical Officer, Restricted Stock Units, RSU award, Insider transaction, Equity compensation, Corporate governance